Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma

Frederick L Locke; David B Miklos; Caron A Jacobson; Miguel-Angel Perales; Marie-José Kersten; Olalekan O Oluwole; Armin Ghobadi; Aaron P Rapoport; Joseph McGuirk; John M Pagel; Javier Muñoz; Umar Farooq; Tom van Meerten; Patrick M Reagan; Anna Sureda; Ian W Flinn; Peter Vandenberghe; Kevin W Song; Michael Dickinson; Monique C Minnema; Peter A Riedell; Lori A Leslie; Sridhar Chaganti; Yin Yang; Simone Filosto; Jina Shah; Marco Schupp; Christina To; Paul Cheng; Leo I Gordon; Jason R Westin; ZUMA-7 Investigators and Contributing Kite Members

doi:10.1056/NEJMoa2116133

Back

Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma

Journal article

Open access

Peer reviewed

Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma

Frederick L Locke, David B Miklos, Caron A Jacobson, Miguel-Angel Perales, Marie-José Kersten, Olalekan O Oluwole, Armin Ghobadi, Aaron P Rapoport, Joseph McGuirk, John M Pagel, …

The New England journal of medicine, Vol.386(7), pp.640-654

02/17/2022

DOI: 10.1056/NEJMoa2116133

PMID: 34891224

Files and links (1)

url

https://pure.eur.nl/en/publications/b7c685f1-382b-415c-bc2c-da1de36915c9View

Open Access

Abstract

In a trial involving patients with relapsed or refractory large B-cell lymphoma, the CAR T-cell therapy axicabtagene ciloleucel led to significantly longer event-free survival than standard salvage chemotherapy (which was followed by high-dose therapy and autologous stem-cell transplantation in patients with a response). High-grade toxic effects were common, but most patients recovered.

Bone Marrow Transplantation

Genetics

Hematology

Leukemia

Oncology

Genetics General

Lymphoma

Treatments in Oncology

Details

Title: Subtitle: Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
Creators: Frederick L Locke - Moffitt Cancer Center
David B Miklos - Stanford University School of Medicine
Caron A Jacobson - Dana-Farber Cancer Institute
Miguel-Angel Perales - Memorial Sloan Kettering Cancer Center
Marie-José Kersten - University of Amsterdam
Olalekan O Oluwole - Vanderbilt-Ingram Cancer Center
Armin Ghobadi - Washington University in St. Louis School of Medicine
Aaron P Rapoport - University of Maryland Medical Center
Joseph McGuirk - The University of Kansas Cancer Center
John M Pagel - Swedish Cancer Institute
Javier Muñoz - Banner MD Anderson Cancer Center
Umar Farooq - University of Iowa
Tom van Meerten - University Medical Center Groningen
Patrick M Reagan - University of Rochester
Anna Sureda - Institut Català d'Oncologia
Ian W Flinn - Sarah Cannon
Peter Vandenberghe - Universitair Ziekenhuis Leuven
Kevin W Song - Vancouver General Hospital
Michael Dickinson - The University of Melbourne
Monique C Minnema - University Medical Center Utrecht
Peter A Riedell - University of Chicago Medical Center
Lori A Leslie
Sridhar Chaganti - University Hospitals Birmingham NHS Foundation Trust
Yin Yang
Simone Filosto
Jina Shah
Marco Schupp
Christina To
Paul Cheng
Leo I Gordon - Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Jason R Westin - The University of Texas MD Anderson Cancer Center
ZUMA-7 Investigators and Contributing Kite Members
Resource Type: Journal article
Publication Details: The New England journal of medicine, Vol.386(7), pp.640-654
DOI: 10.1056/NEJMoa2116133
PMID: 34891224
NLM abbreviation: N Engl J Med
ISSN: 0028-4793
eISSN: 1533-4406
Publisher: Massachusetts Medical Society
Grant note: DOI: 10.13039/100005564, name: Kite, a Gilead company
Language: English
Date published: 02/17/2022
Academic Unit: Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
Record Identifier: 9984359846202771

Metrics

39 Record Views

1168 Times Cited - Web of Science

See more details